{"preliminary_commentary":{"by_channel":{"x_thread":33,"youtube":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03472274\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["durvalumab","tremelimumab"]],"indication":null,"name":"DUTRENEO","nct_id":"NCT03472274","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dutreneo-nct03472274. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DUTRENEO","arms":[{"description":"Patients allocated to the control arm will receive any of the following cisplatin based neoadjuvant treatment:\n\nRegimen 1: Gemcitabine + Cisplatin Regimen 2: Methotrexate + Vinblastine + Doxorubicin + Cisplatin Regimen 3: Gemcitabine + Paclitaxel + Cisplatin","label":"Cisplatin-based neoadjuvant chemotherapy","type":"ACTIVE_COMPARATOR"},{"description":"Patients randomized to experimental arma will receive 28-day treatment cycle x 3 cycles of Durvalumab + Tremelimumab 75 mg every 4 weeks","label":"Durvalumab plus Tremelimumab","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca","Apices Soluciones S.L."],"completion_date":{"date":"2023-04-12","type":"ACTUAL"},"conditions":["Bladder Cancer"],"enrollment":{"count":101,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","otherNames":[],"type":"DRUG"},{"name":"Tremelimumab","otherNames":[],"type":"DRUG"},{"name":"Cisplatin-based neoadjuvant chemotherapy","otherNames":["Standard of care (SoC)"],"type":"DRUG"}],"last_update":"2023-04-13","lead_sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","official_title":"The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients.","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-04-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Antitumor activity","timeFrame":"20 weeks"}],"references":[{"citation":"Sibai M, Cervilla S, Grases D, Musulen E, Lazcano R, Mo CK, Davalos V, Fortian A, Bernat A, Romeo M, Tokheim C, Barretina J, Lazar AJ, Ding L; DUTRENEO Study Investigators; Grande E, Real FX, Esteller M, Bailey MH, Porta-Pardo E. The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity. Cell Rep. 2025 Feb 25;44(2):115229. doi: 10.1016/j.celrep.2024.115229. Epub 2025 Jan 24.","pmid":"39864059","type":"DERIVED"}],"start_date":{"date":"2018-10-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","url":"https://clinicaltrials.gov/study/NCT03472274"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dutreneo-nct03472274"}